Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-09-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-0247PMID 27678458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

  2017cited by this paper
• Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

  2016cited by this paper
• Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

  2016cited by this paper
• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

  2016cited by this paper
• Repair Pathway Choices and Consequences at the Double-Strand Break.

  2016influential reference
• Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

  2016cited by this paper
• FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.

  2016cited by this paper
• Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

  2016cited by this paper
• DNA repair targeted therapy: The past or future of cancer treatment?

  2016cited by this paper
• Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

  2016cited by this paper
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016cited by this paper
• Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

  2016cited by this paper
• REV7 counteracts DNA double-strand break resection and affects PARP inhibition

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

  2015cited by this paper
• Safety evaluation of olaparib for treating ovarian cancer

  2015cited by this paper
• ATM-Dependent Phosphorylation of All Three Members of the MRN Complex: From Sensor to Adaptor

  2015cited by this paper
• Prediction of resistance to chemotherapy in ovarian cancer: a systematic review

  2015cited by this paper
• Cisplatin resistance in germ cell tumours: models and mechanisms

  2015cited by this paper
• Integrative clinical genomics of advanced prostate cancer.

  2015cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

  2015cited by this paper
• PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions

  2015cited by this paper
• Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

  2015cited by this paper
• Targeting the DNA Damage Response in Cancer.

  2015cited by this paper
• Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• ATM and ATR as therapeutic targets in cancer.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

  2015cited by this paper
• Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

  2015cited by this paper
• DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer

  2015cited by this paper
• Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

  2015cited by this paper
• Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

  2015cited by this paper
• A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• 2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis

  2015cited by this paper
• Whole genomes redefine the mutational landscape of pancreatic cancer

  2015cited by this paper
• Mechanisms underlying mutational signatures in human cancers

  2014cited by this paper
• Mutational signatures: the patterns of somatic mutations hidden in cancer genomes

  2014cited by this paper
• Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

  2014cited by this paper
• Beyond DNA repair: DNA-PK function in cancer.

  2014cited by this paper
• Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

  2014cited by this paper
• Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

  2014cited by this paper
• Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.

  2014influential reference
• Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

  2014cited by this paper
• Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment

  2014cited by this paper
• ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.

  2014cited by this paper
• Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

  2014cited by this paper
• DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy

  2014cited by this paper
• PARP inhibitors in ovarian cancer: current status and future promise.

  2014influential reference
• Applying synthetic lethality for the selective targeting of cancer.

  2014cited by this paper
• Exploiting DNA mismatch repair deficiency as a therapeutic strategy.

  2014cited by this paper
• Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors*

  2014cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors

  2013cited by this paper
• Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

  2013cited by this paper
• Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel

  2013cited by this paper
• The ATM protein kinase: regulating the cellular response to genotoxic stress, and more

  2013cited by this paper
• Cisplatin resistance associated with PARP hyperactivation.

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond

  2012cited by this paper
• Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

  2012cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

  2012cited by this paper
• A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy

  2012cited by this paper
• Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

  2012cited by this paper
• Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR.

  2012cited by this paper
• BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.

  2012cited by this paper
• Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

  2012cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.

  2011cited by this paper
• Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

  2011cited by this paper
• miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.

  2011cited by this paper
• ATR signalling: more than meeting at the fork.

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

  2011cited by this paper
• A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers

  2011cited by this paper
• Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

  2011cited by this paper
• A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

  2010cited by this paper
• Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

  2010cited by this paper
• Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells

  2010cited by this paper
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

  2010cited by this paper
• Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

  2009cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

  2008cited by this paper
• Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

  2006cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes*

  2003influential reference
• Mismatch repair and response to DNA-damaging antitumour therapies.

  2003cited by this paper
• Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.

  1999cited by this paper

• Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives

  2025cites this paper
• ATM is associated with the prognosis of colorectal cancer: a systematic review

  2025cites this paper
• The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy.

  2025cites this paper
• A multifunctional manganese-based nanozyme platform for synergistic hypoxia alleviation and cholesterol depletion to potentiate STING-mediated cancer immunotherapy.

  2025cites this paper
• Optogenetic-enhanced Stem Cell Therapy for Neurodegenerative Diseases: A Closed-loop System Integrating Three-dimensional-bioprinted Neural Grafts and Activity-dependent Synaptic Plasticity

  2025cites this paper
• Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions.

  2025cites this paper
• Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

  2024cites this paper
• Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications.

  2024cites this paper
• A perspective on tumor radiation resistance following high-LET radiation treatment

  2024cites this paper
• Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis

  2024cites this paper
• gp78-regulated KAP1 phosphorylation induces radioresistance in breast cancer by facilitating PPP1CC/PPP2CA ubiquitination

  2024cites this paper
• The Inhibition of MSH6 Augments the Antineoplastic Efficacy of Cisplatin in Non-Small Cell Lung Cancer as Autophagy Modulator.

  2024cites this paper
• Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential.

  2024cites this paper
• Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies.

  2024cites this paper
• Metformin overcomes chemoresistance by regulating stemness via KLF4 in oral squamous cell carcinoma.

  2024cites this paper
• Progression in immunotherapy for advanced prostate cancer

  2023cites this paper
• The Combination of ATM and Chk1 Inhibitors Induces Synthetic Lethality in Colorectal Cancer Cells

  2023cites this paper
• Cellular Responses to Widespread DNA Replication Stress

  2023cites this paper
• The RNA m5C modification in R-loops as an off switch of Alt-NHEJ

  2023cites this paper
• Genomic profile of Chinese patients with endometrial carcinoma

  2023cites this paper
• Unraveling MYC’s Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance

  2023cites this paper
• FEN1 promotes cancer progression of cholangiocarcinoma by regulating the Wnt/β-catenin signaling pathway.

  2023cites this paper
• Carrier-Free Nano-PROTACs to Amplify Photodynamic Therapy Induced DNA Damage through BRD4 Degradation.

  2023cites this paper
• Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors.

  2023cites this paper
• Update on Emerging Therapies for Advanced Colorectal Cancer.

  2023cites this paper
• RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma

  2023cites this paper
• Biomarkers of Homologous Recombination Deficiency in the era of PARP inhibitors

  2022cites this paper
• Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

  2022cites this paper
• Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study

  2022cites this paper
• Curcumin delivery and co-delivery based on nanomaterials as an effective approach for cancer therapy

  2022cites this paper
• State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.

  2022cites this paper
• Increased glucose influx and glycogenesis in lung cancer cells surviving after irradiation

  2022cites this paper
• Nanomedicines for Overcoming Cancer Drug Resistance

  2022cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• Lymphocyte-based challenge DNA-repair assays for personalized health risk assessment.

  2022cites this paper
• Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy

  2022cites this paper
• Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.

  2022cites this paper
• Radiogenomics: A Valuable Tool for the Clinical Assessment and Research of Ovarian Cancer

  2022cites this paper
• Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy

  2022cites this paper
• ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage

  2022cites this paper
• Positive Feedback Regulation of Poly(ADP-ribose) Polymerase 1 and the DNA-PK Catalytic Subunit Affects the Sensitivity of Nasopharyngeal Carcinoma to Etoposide

  2022cites this paper
• PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.

  2021cites this paper
• The promise of DNA damage response inhibitors for the treatment of glioblastoma

  2021cites this paper
• Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer

  2021cites this paper
• Tumor Profiling at the Service of Cancer Therapy

  2021cites this paper
• Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

  2021cites this paper
• DNA repair genes are associated with tumor tissue differentiation and immune environment in lung adenocarcinoma: a bioinformatics analysis based on big data

  2021cites this paper
• hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors

  2021cites this paper
• The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer

  2021cites this paper
• MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors

  2021cites this paper
• NONO phase separation enhances DNA damage repair by accelerating nuclear EGFR-induced DNA-PK activation.

  2021cites this paper
• A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries

  2021cites this paper
• Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

  2021cites this paper
• SIRT7: a sentinel of genome stability

  2021cites this paper
• Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours

  2021cites this paper
• Interaction of hydrogen peroxide molecules with non-specific DNA recognition sites

  2020cites this paper
• Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer

  2020cites this paper
• PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.

  2020cites this paper
• Telomere maintenance in interplay with DNA repair in pathogenesis and treatment of colorectal cancer.

  2020cites this paper
• Exosomes carrying ALDOA and ALDH3A1 from irradiated lung cancer cells enhance migration and invasion of recipients by accelerating glycolysis

  2020cites this paper
• Curcumin effect on cancer cells' multidrug resistance: An update

  2020cites this paper
• Vinpocetine reduces cisplatin-induced acute kidney injury through inhibition of NF–κB pathway and activation of Nrf2/ARE pathway in rats

  2020cites this paper
• PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

  2020cites this paper
• Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy.

  2020cites this paper
• BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

  2020cites this paper
• Homologous recombination deficiency real-time clinical assays, ready or not?

  2020cites this paper
• DNA repair pathways as guardians of the genome: Therapeutic potential and possible prognostic role in hematologic neoplasms.

  2020cites this paper
• Regulation and pharmacological targeting of RAD51 in cancer

  2020cites this paper
• Clinical assays for assessment of homologous recombination DNA repair deficiency.

  2020cites this paper
• Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy

  2020cites this paper
• DNA Repair-Based Gene Expression Signature and Distinct Molecular Subtypes for Prediction of Clinical Outcomes in Lung Adenocarcinoma

  2020cites this paper
• The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability

  2020cites this paper
• Emerging therapeutic targets for patients with advanced prostate cancer.

  2019cites this paper
• Crystal structure of Tdp1 catalytic domain in complex with compound XZ578

  2019cites this paper
• Automodified Poly(ADP-Ribose) Polymerase Analysisto Monitor DNA Damagein Peripheral Lymphocytes of Floriculturists Occupationally Exposed to Pesticides

  2019cites this paper
• DNA repair capacity and response to treatment of colon cancer.

  2019cites this paper
• CMAR_A_208720 10463..10476

  2019influential citation
• First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

  2019influential citation
• Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.

  2019cites this paper
• Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting

  2019cites this paper
• Retracted Article: Aclarubicin regulates glioma cell growth and DNA damage through the SIRT1/PI3K/AKT signaling pathway

  2019cites this paper
• Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers

  2019cites this paper
• Biomarkers of Gynecological Cancers

  2019cites this paper
• 'Stemness' and 'senescence' related escape pathways are dose dependent in lung cancer cells surviving post irradiation.

  2019cites this paper
• Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening.

  2019cites this paper
• DNA damage and repair measured by comet assay in cancer patients.

  2019cites this paper
• PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma

  2019cites this paper
• Emerging targets in cancer drug resistance

  2019cites this paper
• N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.

  2019cites this paper
• FUNCTIONAL INSIGHTS INTO RAD51 REGULATORY PROTEINS IN HOMOLOGOUS RECOMBINATION

  2019influential citation
• Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.

  2019cites this paper
• Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

  2019cites this paper
• 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

  2019cites this paper
• Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies

  2018cites this paper
• The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

  2018cites this paper
• Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors

  2018cites this paper
• The Inhibition of DNA Damage Response Contributes to Cancer Radiotherapy

  2018cites this paper
• RAD-ical New Insights into RAD51 Regulation

  2018cites this paper
• Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients.

  2018cites this paper